Rafael Pharma receives fast track designation from USFDA for the treatment of pancreatic cancer


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Rafael Pharma receives fast track designation from USFDA for the treatment of pancreatic cancer
With this designation, cancer metabolism is truly being propelled forward, with devimistat at the helm

Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613 (devimistat), for the treatment of metastatic pancreatic cancer.

“Receiving Fast Track designation is a significant milestone in our fight against pancreatic cancer,” said Sanjeev Luther, President and CEO of Rafael. “This designation further stresses the severe unmet need in treatment options for this aggressive and devastating disease. We are truly thankful to the doctors, researchers, the FDA and all of our supporters who have made this possible. And most of all, we are grateful to the patients involved in our trials; the patients are the inspiration and driving force behind all of our efforts.”

Rafael has continued to reach milestones throughout the year, including achieving its target enrollment of 500 patients for its Phase 3 trial for metastatic pancreatic cancer ahead of schedule. The Company also recently announced that the FDA granted devimistat Orphan Drug Designation for the treatment of soft tissue sarcoma.

“Pancreatic cancer is notoriously challenging to treat and long overdue for a new approach,” said Philip A. Philip, M.D., Ph.D., FRCP, Professor of Oncology at the Barbara Ann Karmanos Cancer Institute at Wayne State University and a medical advisor to Rafael. “We have remained hopeful throughout our pancreatic cancer trials, and now with Fast Track designation, our optimism is further fueled. We believe with this designation, cancer metabolism is truly being propelled forward, with devimistat at the helm.”

CPI-613 (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Devimistat is designed to target the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumour cell multiplication and survival, selectively in cancer cells. Devimistat substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents. This synergy allows for potential combinations of devimistat with lower doses of these generally toxic drugs to be more effective with lower patient’s side effects. Combination with devimistat represents a diverse range of opportunities to substantially improve patient’s benefit in many different cancers. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal Phase 3 clinical trials in pancreatic cancer (AVENGER 500) and acute myeloid leukemia (ARMADA 2000), and has designated devimistat as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, peripheral T-cell lymphoma, Burkitt’s lymphoma and soft tissue sarcoma. The EMA has granted orphan drug designation to devimistat for pancreatic cancer and acute myeloid leukemia.

Tags : #RafaelPharmaceuticals #LatestNewsonRafaelPharmaceuticals11thNov #LatestUSFDADesignation11thNov #LatestPharmaNews11thNov #LatestResearchonMetastaticPancreaticCancer11thNov #CancerMetabolism

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Richest 1% people have enough new wealth to end annual poverty 22 times overJuly 11, 2025
Fermenta Signs Strategic MoU with NIFTEM-T to Strengthen India’s Food Fortification LandscapeJuly 11, 2025
Sarvodaya Hospital, Greater Noida West, Launches Next-Gen Fully Active Robotic System for Joint ReplacementJuly 10, 2025
Children Dazzle the Stage at Faridabad Talent Hunt at Asian Institute of Medical SciencesJuly 10, 2025
From Macro to Mandate: How India's Affluent Investors are Positioning for Global ShiftsJuly 10, 2025
Actress-turned-Entrepreneur raises alarm over hidden pet health crisis in IndiaJuly 10, 2025
Aster CMI Performs Complex Tracheal Resection and Anastomosis to Cure Chronic BreathlessnessJuly 10, 2025
CARE Hospitals, Hitech City introduces India’s Most Advanced AI-Powered Robotic Surgery SystemJuly 09, 2025
Nestlé India Supports Flood Relief Efforts in Himachal PradeshJuly 09, 2025
When Machines Whisper Care: The Quiet Rise of Medical Bots in Elderly WardsJuly 09, 2025
Integrating mental health into India’s primary healthcare, what’s next?July 09, 2025
Where the Mind Finds Rest: How Green Spaces Quiet the City NoiseJuly 09, 2025
Can a Smartphone Heal Your Wound?July 09, 2025
University of Birmingham Dubai invites applications for MSc in Financial Data ScienceJuly 08, 2025
Benefits of ShirodharaJuly 07, 2025
WIKA India Launches “Re-Inventing Hygiene” Campaign to Advance Standards in Food & Pharma InstrumentationJuly 07, 2025
Cambodia is 2nd Asian country to rollout long-acting injectable HIV prevention optionJuly 07, 2025
Wheels of Care: How Tele-MRVs Are Reaching Mothers Left BehindJuly 07, 2025
Personalized Psychiatry's Developing Use of PharmacogenomicsJuly 07, 2025
Honourable Ministers Shri Anil Kumar Bachoo and Shri Palanivel Thiaga Rajan Open IIRSI 2025 Convention on Intraocular Implant & Refractive SurgeryJuly 05, 2025